Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Mode of action and clinical studies with alemtuzumab.

Jones JL, Coles AJ.

Exp Neurol. 2014 Dec;262 Pt A:37-43. doi: 10.1016/j.expneurol.2014.04.018. Epub 2014 May 2. Review.

PMID:
24792641
2.

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

Brown JW, Coles AJ.

Drug Des Devel Ther. 2013;7:131-8. doi: 10.2147/DDDT.S32687. Epub 2013 Mar 6. Review.

3.

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S.

J Immunol. 2013 Dec 15;191(12):5867-74. doi: 10.4049/jimmunol.1301926. Epub 2013 Nov 6.

4.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Hersh CM, Cohen JA.

Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7. Review.

PMID:
24762071
5.

[Alemtuzumab, a monoclonal antibody against CD52: hopes and fears].

Mori M.

Brain Nerve. 2014 Oct;66(10):1179-89. doi: 10.11477/mf.1416200007. Japanese.

PMID:
25296872
6.

Multiple sclerosis: reprogramming the immune repertoire with alemtuzumab in MS.

Wiendl H, Kieseier B.

Nat Rev Neurol. 2013 Mar;9(3):125-6. doi: 10.1038/nrneurol.2013.2. Epub 2013 Jan 29.

PMID:
23358486
7.

Alemtuzumab treatment of multiple sclerosis.

Coles AJ.

Semin Neurol. 2013 Feb;33(1):66-73. doi: 10.1055/s-0033-1343797. Epub 2013 May 25. Review.

PMID:
23709214
8.

The outlook for alemtuzumab in multiple sclerosis.

Williams T, Coles A, Azzopardi L.

BioDrugs. 2013 Jun;27(3):181-9. doi: 10.1007/s40259-013-0028-3.

PMID:
23558379
9.

ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.

Ruck T, Afzali AM, Lukat KF, Eveslage M, Gross CC, Pfeuffer S, Bittner S, Klotz L, Melzer N, Wiendl H, Meuth SG.

BMC Neurol. 2016 Mar 10;16:34. doi: 10.1186/s12883-016-0556-9.

10.

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ.

Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21.

11.

[Alemtuzumab: a further option for treatment of multiple sclerosis].

Menge T, Kieseier BC, Warnke C, Aktas O, Hartung HP.

Nervenarzt. 2012 Apr;83(4):487-501. doi: 10.1007/s00115-011-3393-5. German.

PMID:
22038387
12.

Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro.

Havari E, Turner MJ, Campos-Rivera J, Shankara S, Nguyen TH, Roberts B, Siders W, Kaplan JM.

Immunology. 2014 Jan;141(1):123-31. doi: 10.1111/imm.12178.

13.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK.

N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.

14.

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Cuker A, Coles AJ, Sullivan H, Fox E, Goldberg M, Oyuela P, Purvis A, Beardsley DS, Margolin DH.

Blood. 2011 Dec 8;118(24):6299-305. doi: 10.1182/blood-2011-08-371138. Epub 2011 Sep 29.

15.

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond.

Ruck T, Bittner S, Wiendl H, Meuth SG.

Int J Mol Sci. 2015 Jul 20;16(7):16414-39. doi: 10.3390/ijms160716414. Review.

16.

Alemtuzumab therapy for multiple sclerosis.

Coles AJ.

Neurotherapeutics. 2013 Jan;10(1):29-33. doi: 10.1007/s13311-012-0159-0. Review.

17.
18.

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Hartung HP, Aktas O, Boyko AN.

Mult Scler. 2015 Jan;21(1):22-34. doi: 10.1177/1352458514549398. Epub 2014 Oct 24. Review.

19.

[Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies].

Klotz L, Meuth SG, Kieseier B, Wiendl H.

Nervenarzt. 2013 Aug;84(8):984-94. doi: 10.1007/s00115-013-3814-8. German.

PMID:
23793409
20.

Campath-1H treatment of multiple sclerosis.

Jones JL, Coles AJ.

Neurodegener Dis. 2008;5(1):27-31. Review.

PMID:
18075272
Items per page

Supplemental Content

Write to the Help Desk